Morlando M, Pelullo CP, Di Giuseppe G. Prostate cancer screening: knowledge, attitudes and practices in a sample of men in Italy. A survey. PLoS ONE. 2017;12:e0186332.

Article  PubMed  PubMed Central  Google Scholar 

Brunner C, Davies NM, Martin RM, Eeles R, Easton D, Kote-Jarai Z, et al. Alcohol consumption and prostate cancer incidence and progression: a mendelian randomisation study. Int J Cancer. 2017;140:75–85.

Article  CAS  PubMed  Google Scholar 

Park S, Kim YJ, Jon S. A high-affinity peptide for nicotinic acetylcholine receptor-α1 and its potential use in pulmonary drug delivery. JCR. 2014;192:141–7.

Article  CAS  Google Scholar 

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. Ca Cancer J Clin. 2023;73:17–48.

Article  PubMed  Google Scholar 

Jewett MA, Fleshner N, Klotz LH, Nam RK, Trachtenberg J. Radical prostatectomy as treatment for prostate cancer. CMAJ. 2003;168:44–5.

PubMed  PubMed Central  Google Scholar 

Khan FM, Gibbons JP. Khan’s the physics of radiation therapy. Lippincott Williams & Wilkins; 2014.

Fleshner N, Al Azab R. Prostate cancer: chemoprevention update. CJU. 2005;12:2–4.

Google Scholar 

Djavan B, Nasu Y. Prostate cancer gene therapy- what have we learned and where are we going? Rev. 2001;3:179.

CAS  Google Scholar 

Chen FZ, Zhao XK. Prostate cancer: current treatment and prevention strategies. IRCMJ. 2013;15:279.

PubMed  PubMed Central  Google Scholar 

Symonds RP, Foweraker K. Principles of chemotherapy and radiotherapy. Curr Obstet Gynaecol. 2006;16:100–6.

Article  Google Scholar 

Junquera JA, Suarez MH, García JA, García RA, Suárez HG, Alonso A, et al. Brachytherapy in localized prostate cancer. Actas Urol Esp. 2007;31:617–26.

Google Scholar 

Symonds RP. Principles of gynaecological chemotherapy and radiotherapy. Curr Obstet Gynaecol. 2003;13:102–9.

Article  Google Scholar 

Zhang X, Cai W, Cao F, Schreibmann E, Wu Y, Wu JC, et al. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med. 2006;47:492–501.

CAS  PubMed  Google Scholar 

Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020;19:589–608.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alsharef SH, Alanazi MA, Alharthi FA, Qandil DA, Qushawy MO. Review about radiopharmaceuticals: preparation, radioactivity, and applications. Int J App Pharm. 2020;12:8–15.

Article  CAS  Google Scholar 

Nitipir C, Niculae D, Orlov C, Barbu MA, Popescu B, Popa AM, et al. Update on radionuclide therapy in oncology. Oncol Lett. 2017;14:7011–5.

PubMed  PubMed Central  Google Scholar 

Camus B, Cottereau AS, Palmieri LJ, Dermine S, Tenenbaum F, Brezault C, et al. Indications of peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic and pulmonary neuroendocrine tumors: an updated review. J Clin Med. 2021;10:1267.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Czerwińska M, Bilewicz A, Kruszewski M, Wegierek-Ciuk A, Lankoff A. Targeted radionuclide therapy of prostate cancer—from basic research to clinical perspectives. Mol. 2020;25:1743.

Article  Google Scholar 

Ananias HJ, Yu Z, Dierckx RA, van der Wiele C, Helfrich W, Wang F, et al. 99mtechnetium-HYNIC (tricine/TPPTS)-Aca-bombesin (7–14) as a targeted imaging agent with microSPECT in a PC-3 prostate cancer xenograft model. Mol Pharm. 2011;8:1165–73.

Article  CAS  PubMed  Google Scholar 

Ferro-Flores G, de Murphy CA, Rodr J, Pedraza-Lo M. Preparation and evaluation of 99mTc-EDDA/HYNIC-[Lys3]-bombesin for imaging gastrin-releasing peptide receptor-positive tumours. Nucl Med Commun. 2006;27:371–6.

Article  CAS  PubMed  Google Scholar 

Mohammadgholi M, Rezazadeh F, Abediankenari S, Abedi SM, Emrarian I, Jafari N, et al. Evaluation of new 99mTc-labeled HYNIC-bombesin analogue for prostate cancer imaging. J Radioanal Nucl Chem. 2018;316:595–607.

Article  CAS  Google Scholar 

Melendez-Alafort L, Ferro-Flores G, Arteaga-Murphy C, Pedraza-Lopez M, Gonzalez-Zavala MA, Tendilla JI, et al. Labeling peptides with rhenium-188. Int J Pharm. 1999;182:165–72.

Article  CAS  PubMed  Google Scholar 

Luo TY, Cheng PC, Chiang PF, Chuang TW, Yeh CH, Lin WJ. 188Re-HYNIC-trastuzumab enhances the effect of apoptosis induced by trastuzumab in HER2-overexpressing breast cancer cells. Ann Nucl Med. 2015;29:52–62.

Article  CAS  PubMed  Google Scholar 

Blower PJ. Rhenium-188 radiochemistry: challenges and prospects. Int J Nucl Med Res. 2017;31:39–53.

Google Scholar 

Zamora PO, Marek MJ, Knapp FR Jr. Preparation of 188Re-RC-160 somatostatin analog: a peptide for local/regional radiotherapy. Appl Radiat Isot. 1997;48:305–9.

Article  CAS  PubMed  Google Scholar 

de Murphy CA, Pedraza-López M, Ferro-Flores G, Murphy-Stack E, Chávez-Mercado L, Ascencio JA, et al. Uptake of 188Re-β-naphthyl-peptide in cervical carcinoma tumors in athymic mice. Nucl Med Biol. 2001;28:319–26.

Article  Google Scholar 

Molina-Trinidad EM, de Murphy CA, Ferro-Flores G, Murphy-Stack E, Jung-Cook H. Radiopharmacokinetic and dosimetric parameters of 188Re-lanreotide in athymic mice with induced human cancer tumors. Int J Pharm. 2006;310:125–30.

Article  CAS  PubMed  Google Scholar 

Cyr JE, Pearson DA, Wilson DM, Nelson CA, Guaraldi M, Azure MT, et al. Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies. J Med Chem. 2007;50:1354–64.

Article  CAS  PubMed  Google Scholar 

Yu F, Lv M, Cai H, Li D, Yuan X, Lv Z. Therapeutic effect of 188Re-MAG3-depreotide on non-small cell lung cancer in vivo and in vitro. Int J Clin Exp Pathol. 2013;6:421.

CAS  PubMed  PubMed Central  Google Scholar 

Cui L, Liu Z, Jin X, Jia B, Li F, Wang F. Evaluation of 188Re-MAG2-RGD-bombesin for potential prostate cancer therapy. Nucl Med Biol. 2013;40:182–9.

Article  PubMed  Google Scholar 

Lepareur N, Lacœuille F, Bouvry C, Hindré F, Garcion E, Chérel M, et al. Rhenium-188 labeled radiopharmaceuticals: current clinical applications in oncology and promising perspectives. Front Med. 2019;6:132.

Article  Google Scholar 

Sharifi M, Yousefnia H, Bahrami-Samani A, Jalilian AR, Zolghadri S, Alirezapour B, et al. Optimized production, quality control, biological evaluation and PET/CT imaging of 68Ga-PSMA-617 in breast adenocarcinoma model. Radiochim Acta. 2017;105:399–407.

Article  CAS  Google Scholar 

Sharifi M, Jalilian AR, Yousefnia H, Alirezapour B, Bahrami-Samani A, Zolghadri S. Production, quality control, biodistribution and imaging studies of 177Lu-PSMA-617 in breast adenocarcinoma model. Radiochim Acta. 2018;106:507–13.

Article  CAS  Google Scholar 

Yousefnia H, Mousavi-Daramoroudi MS, Zolghadri S, Abbasi-Davani F. Preparation and biodistribution assessment of low specific activity 177 Lu-DOTATOC for optimization studies. Iran J Nucl Med. 2016; 24.

Mather SJ, Nock BA, Maina T, Gibson V, Ellison D, Murray I, et al. GRP receptor imaging of prostate cancer using [99m tc] demobesin 4: a first-in-man study. Mol Imaging Biol. 2014;16:888–95.

Article  PubMed  Google Scholar 

Nock BA, Kaloudi A, Kanellopoulos P, Janota B, Bromińska B, Iżycki D, et al. [99mTc] Tc-DB15 in GRPR-targeted tumor imaging with SPECT: from preclinical evaluation to the first clinical outcomes. Cancers. 2021;13:5093.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Van de Wiele C, Dumont F, Vanden Broecke R, Oosterlinck W, Cocquyt V, Serreyn R, et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med. 2000;27:1694–9.

Article  PubMed  Google Scholar 

Chernov V, Rybina A, Zelchan R, Medvedeva A, Bragina O, Lushnikova N, et al. Phase I trial of [99mTc] Tc-MaSSS-PEG2-RM26, a Bombesin Analogue antagonistic to gastrin-releasing peptide receptors (GRPRs), for SPECT Imaging of GRPR expression in malignant tumors. Cancers. 2023;15:1631.

Article  CAS  PubMed  PubMed Central  Google Scholar